On 26 April 2012, orphan designation (EU/3/12/987) was granted by the European Commission to JJGConsultancy Ltd, United Kingdom, for (E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt for the treatment of myelodysplastic syndromes.
The sponsorship was transferred to Onconova Europe GmbH, Germany, in February 2014.
The sponsor’s address was updated in March 2021.
EU/3/12/987: Public summary of opinion on orphan designation: (E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt for the treatment of myelodysplastic syndromes (PDF/129.92 KB)
First published: 18/06/2012
Last updated: 08/05/2014
EMA/COMP/217857/2012 Rev. 1
(E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt
|Disease / condition||
Treatment of myelodysplastic syndromes
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.